---
title: "Novo Nordisk Improves 2026 Earnings Outlook, Discusses GLP-1 Sales"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294851081.md"
description: "Novo Nordisk AS expects adjusted sales for the current fiscal year to range from -6% to 0% year-on-year on a constant currency basis, in line with market expectations. The second quarter saw strong performance, with adjusted sales rising 7% to DKK 78.49 billion and operating profit increasing 11% to DKK 33.39 billion on a constant currency basis. The company also highlighted an improved earnings outlook for 2026 and discussed GLP-1 drug sales"
datetime: "2026-08-04T16:36:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294851081.md)
  - [en](https://longbridge.com/en/news/294851081.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294851081.md)
---

# Novo Nordisk Improves 2026 Earnings Outlook, Discusses GLP-1 Sales

Novo Nordisk AS expects adjusted sales for the current fiscal year to range from -6% to 0% year-on-year on a constant currency basis, compared to market expectations of -5.9%. Adjusted sales in the second quarter grew 7% on a constant currency basis; adjusted operating profit rose 11% on a constant currency basis. Adjusted sales in the second quarter amounted to DKK 78.49 billion; adjusted operating profit reached DKK 33.39 billion.

Risk Warning and Disclaimer

The market involves risks, and investment should be approached with caution. This article does not constitute personal investment advice, nor does it take into account the specific investment objectives, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions presented in this article align with their specific circumstances. Investors bear full responsibility for any investment decisions made based on this content.

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NVOH.US](https://longbridge.com/en/quote/NVOH.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)

## Related News & Research

- [Novo CEO faces investor grilling after outlook hike soured by pipeline concerns](https://longbridge.com/en/news/294922727.md)
- [Novo Nordisk Probes Thyroid Cancer Risk in Real‑World GLP‑1 Users](https://longbridge.com/en/news/294850678.md)
- [Novo Nordisk Lifts 2026 Guidance as Wegovy Pill Drives Q2 Obesity Growth](https://longbridge.com/en/news/294884693.md)
- [Novo Nordisk A/S - share repurchase programme | NVO Stock News](https://longbridge.com/en/news/294835686.md)
- [GLP-1 drugs could become personalized for individuals, study says](https://longbridge.com/en/news/294501170.md)